Gaboxadol - Wikipedia, the free encyclopedia
Gaboxadol was an experimental sleeping pill developed by Lundbeck and Merck. In March, 2007, Merck and H. Lundbeck cancelled work on the drug, citing safety concerns and the ...
Dissociative - Wikipedia, the free encyclopedia
Gaboxadol; Ibotenic acid (found in Amanita muscaria ("Fly Agaric")) (prodrug to muscimol) Muscimol (found in Amanita muscaria ("Fly Agaric")) Sigma σ 1 /σ 2 Receptor Agonists
A Study of Gaboxadol in Primary Insomnia - Full Text View ...
Study Type: Interventional: Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study: Official Title: A Prospective Randomised Double ...
Effect of short-term treatment with gaboxadol on sleep ...
Gaboxadol 15 mg also significantly reduced mean latency to persistent sleep ... Gaboxadol also enhanced slow wave sleep duration and had no significant effects ...
Treatment of depression and other affective disorders
The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol ...
Merck, Lundbeck scrap insomnia drug after trials | Reuters
... were ending studies of experimental insomnia drug gaboxadol due to disappointing ... Merck has said gaboxadol, which works through a different mechanism of action ...
The Science of Sleep: Scientists Spot Mechanism Behind ...
An experimental drug called gaboxadol may soon help millions of bleary-eyed ... What's more, gaboxadol's unique mechanism of action could keep it from ...
Neuropsychopharmacology - Abstract of article: Effect of ...
Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology, publishing the ... Since gaboxadol, a selective GABAA ...
Scientists Spot Mechanism Behind Promising New Sleep Drug
An experimental drug called gaboxadol may soon help millions of bleary-eyed insomniacs get to sleep, and a multi-center team of U.S. scientists believes they've pinpointed just how ...
Merck & Co., Inc. and Lundbeck End Development of Insomnia ...
... today the discontinuation of their joint development program for gaboxadol, ... the overall clinical profile for gaboxadol in insomnia does not support ...
